

# AVANTAGE - Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

Head :Medical data center

Last update : 02/04/2022 | Version : 1 | ID : 74114

General	
Identification	
Detailed name	Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice
Sign or acronym	AVANTAGE
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	ML28621
General Aspects	
Medical area	Cancer research
Study in connection with Covid-19	No
Pathology (details)	Non-squamous non-small cell lung cancer
Health determinants	Medicine
Keywords	Bevacizumab
Scientific investigator(s) (Contact)	
Name of the director	Medical data center
Email	data_sharing_france@roche.com
Organization	Roche SAS
Collaborations	
Participation in projects, networks and consortia	No

## Funding

Funding status	Private
----------------	---------

## Governance of the database

Sponsor(s) or organisation(s) responsible	Roche SAS
---	-----------

Organisation status	Private
---------------------	---------

Presence of scientific or steering committees	Yes
---	-----

## Additional contact

## Main features

## Type of database

Type of database	Study databases
------------------	-----------------

Study databases (details)	Cohort study
---------------------------	--------------

Database recruitment is carried out by an intermediary	A selection of health institutions and services
--	---

Database recruitment is carried out as part of an interventional study	No
--	----

## Database objective

Main objective	<p>In each cohort of patients defined by their age classification ([65; 70[ and <math>\geq 70</math> years), outcome measures are as follows:</p> <ul style="list-style-type: none"><li>- Antineoplastic agents combined with bevacizumab as 1st line therapy</li><li>- Classes of antineoplastic agents combined with bevacizumab as 1st line therapy (platinum salt, taxanes,...)</li><li>- Supportive care (growth factors, analgesics).</li></ul> <p>to describe:</p> <ul style="list-style-type: none"><li>- Characteristics of advanced nsNSCLC patients treated with bevacizumab as first-line therapy, and their disease characteristics,</li><li>- Progression-Free Survival (PFS) and Overall Survival (OS),</li><li>- Evolution of patients' quality of life over the treatment period with bevacizumab as first-line therapy,</li><li>- Safety of bevacizumab,</li></ul>
----------------	--

- Reasons for non-use of bevacizumab as first-line therapy in patients suffering from advanced nsNSCLC.

Inclusion criteria	Inclusion criteria : <ul style="list-style-type: none"><li>- Patient aged <math>\geq 65</math> years,</li><li>- Diagnosed with advanced nsNSCLC (stage IIIB or IV),</li><li>- For whom the physician has decided to initiate a treatment with bevacizumab combined with chemotherapy as 1st line therapy,</li><li>- Having received oral and written information about the study, and having signed a written consent form.</li></ul>
Population type	
Age	Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
Gender	Male Woman
Geography area	National
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2013
Date of last collection (YYYY or MM/YYYY)	2017
Size of the database	
Size of the database (number of individuals)	< 500 individuals
Details of the number of individuals	277
Data	
Database activity	Data collection completed

Type of data collected	Clinical data
Clinical data (detail)	Medical registration
Details of collected clinical data	Validation of selection criteria ; Information about the study and written consent form ; Demographic and general data ; Disease history ; Bevacizumab treatment ; G8 index and comorbidity index of Charlson, if done ; Response to first-line treatment ; Combined treatments ; First disease progression ; Patient-reported outcomes ; Reason of withdrawal ; Adverse events.
Presence of a biobank	No
Procedures	
Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor
Followed pathology	C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Dedicated website	<a href="https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html">https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html</a>
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only